Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eciskafusp alfa alone or with atezolizumab in advanced solid tumors
NCT04303858Phase 1Terminated
- Sponsor
- Roche
- Start
- May 2020
- Primary completion
- Oct 2025
- Modality
- Immunomodulatory ADCs, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of eciskafusp alfa in solid tumor (3 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events up to 1.5 months, Percentage of Participants with Dose-Limiting Toxicities and 2 more. Started May 2020; status: terminated.
02
Drugs
eciskafusp alfa
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04303858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303858.